Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients

Unfortunately, most patients are already at a very advanced stage when they are diagnosed with lung cancer, i.e. the cancer has already spread outside the lungs forming metastases. The current standard of care therapy at this advanced stage of lung cancer includes systemic anti-cancer therapy such as chemotherapy, immunotherapy to boost the body's immune response, or targeted therapy that directly hinders tumor growth. In this study, the aim is to find out whether it is better if, after a good response to the standard therapy, the remains of main tumor and the metastases are additionally treat

Trial Details

NCT ID
NCT06114108
Phase
NA
Sponsor
Swiss Cancer Institute
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy)
  • Surgery
  • Radiotherapy
Locations (sample)
  • Aarau, Switzerland|47.39254,8.04422
  • Bellinzona, Switzerland|46.19278,9.01703
  • Chur, Switzerland|46.84986,9.53287
  • Fribourg, Switzerland|46.80237,7.15128
  • Geneva, Switzerland|46.20222,6.14569

Key Eligibility Criteria

  • Patients fulfilling all of the following inclusion criteria at screening may be enrolled in the trial.
  • The inclusion criteria are irrespective from the tumor burden at the time of primary diagnosis before initiation of first line systemic therapy. Tr…
  • Adults (18 years or older)
  • Tissue confirmed, pre-treatment clinical stage IV NSCLC

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →